Acurx Pharmaceuticals, Inc. Operating Cash Flow
Acurx Pharmaceuticals, Inc. (ACXP) reported Operating Cash Flow of -$3.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.71M.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.41M.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.18M.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.88M.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$6.79M.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$10.38M.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$9.80M.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$7.54M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$3.12M 10-Q · filed 2026-08-13 | -$4.30M derived: sum of 3 quarters · filed 2026-08-13 | -$6.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.41M 10-Q · filed 2026-05-11 | -$2.59M derived: sum of 2 quarters · filed 2026-05-11 | -$4.47M derived: sum of 3 quarters · filed 2026-05-11 | -$6.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$3.07M derived: sum of 2 quarters · filed 2026-03-12 | -$4.74M derived: sum of 3 quarters · filed 2026-08-13 | -$6.79M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$3.55M derived: sum of 2 quarters · filed 2026-08-13 | -$5.60M 10-Q · filed 2025-11-12 | -$7.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$3.72M 10-Q · filed 2026-08-13 | -$5.97M derived: sum of 3 quarters · filed 2026-08-13 | -$8.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$2.05M 10-Q · filed 2026-05-11 | -$4.30M derived: sum of 2 quarters · filed 2026-05-11 | -$6.49M derived: sum of 3 quarters · filed 2026-05-11 | -$9.37M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$4.44M derived: sum of 2 quarters · filed 2026-03-12 | -$7.32M derived: sum of 3 quarters · filed 2026-03-12 | -$10.38M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$5.07M derived: sum of 2 quarters · filed 2025-11-12 | -$8.13M 10-Q · filed 2025-11-12 | -$12.33M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$5.94M 10-Q · filed 2025-08-11 | -$10.14M derived: sum of 3 quarters · filed 2025-08-11 | -$12.23M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$3.06M 10-Q · filed 2025-05-12 | -$7.26M derived: sum of 2 quarters · filed 2025-05-12 | -$9.35M derived: sum of 3 quarters · filed 2025-05-12 | -$10.93M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$6.29M derived: sum of 2 quarters · filed 2025-03-17 | -$7.87M derived: sum of 3 quarters · filed 2025-03-17 | -$9.80M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$3.67M derived: sum of 2 quarters · filed 2024-11-12 | -$5.60M 10-Q · filed 2024-11-12 | -$7.10M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.51M 10-Q · filed 2024-08-08 | -$5.01M derived: sum of 3 quarters · filed 2024-08-08 | -$7.19M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.93M 10-Q · filed 2024-05-14 | -$3.43M derived: sum of 2 quarters · filed 2024-05-14 | -$5.61M derived: sum of 3 quarters · filed 2024-05-14 | -$7.60M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$3.68M derived: sum of 2 quarters · filed 2024-03-15 | -$5.67M derived: sum of 3 quarters · filed 2024-03-15 | -$7.54M 10-K · filed 2024-03-15 |
| 2022-09-30 | -$2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$4.17M derived: sum of 2 quarters · filed 2023-11-13 | -$6.05M 10-Q · filed 2023-11-13 | -$7.55M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$3.87M 10-Q · filed 2023-08-11 | -$5.37M derived: sum of 3 quarters · filed 2023-08-11 | -$8.00M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$1.88M 10-Q · filed 2023-05-12 | -$3.38M derived: sum of 2 quarters · filed 2023-05-12 | -$6.01M derived: sum of 3 quarters · filed 2023-05-12 | -$6.34M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$4.14M derived: sum of 2 quarters · filed 2023-03-15 | -$4.47M derived: sum of 3 quarters · filed 2023-03-15 | -$5.01M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$2.97M derived: sum of 2 quarters · filed 2022-11-10 | -$3.51M 10-Q · filed 2022-11-10 | -$4.47M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$329.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$876.95K 10-Q · filed 2022-08-12 | -$1.84M derived: sum of 3 quarters · filed 2022-08-12 | -$2.60M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$547.14K 10-Q · filed 2022-05-10 | -$1.51M derived: sum of 2 quarters · filed 2022-05-10 | -$2.27M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$959.75K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | -$1.72M derived: sum of 2 quarters · filed 2022-03-16 | -$3.35M 10-K · filed 2022-03-16 | |
| 2020-09-30 | -$758.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$2.39M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$1.63M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |